Neil H. Bander, MD, discusses preliminary results from a phase 1/2 study of pembrolizumab in combination with an androgen-receptor signaling inhibitor and alpha-PSMA-targeted radionuclide therapy in mCRPC.
Kala Visvanathan, MD, MBBS, MHS, discusses the rationale for evaluating lipophilic statins in epithelial ovarian cancer.
For many people who go into research, there’s a moment somewhere along the way that is immediately addictive and makes you want to experience that over and over again.
Francesco Di Meo, PhD, discusses the rationale for targeting LILRB4 through CAR T-cell therapy in multiple myeloma.
Lori A. Leslie, MD, discusses the evolution in managing toxicities associated with CAR T-cell therapy in patients with LBCL.
Jeremy M. Pantin, MD, discusses the evolution of the PNH treatment paradigm and agents that are available or being investigated in this disease.
Corey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.
Rosa M. Polan, MD, discusses key data from a comparison of perioperative outcomes with supracervical and total hysterectomy performed with concurrent colorectal resection in women.
Saurabh Dahiya, MBBS, discusses real-world data observed from a long-term follow-up of axicabtagene ciloleucel in large B-cell lymphoma.
Zarnie Lwin, MBBS, FRACP, discusses patient selection, including those with colorectal cancer, for the phase 2 LEAP-005 study.
Seeking a second opinion, Arthur “Art” Gillespie turned to Northwestern Medicine for a life-saving double-lung transplant procedure.
Leading cancer biologist Julio Aguirre-Ghiso, PhD, has been named founding director of the Cancer Dormancy and Tumor Microenvironment Institute, director of the Gruss-Lipper Biophotonics Center, and co-leader of the AECC Tumor Microenvironment and Metastasis Program.
Shaji Kumar, MD and Jonathan Kaufman, MD, discuss unmet needs in the multiple myeloma treatment landscape and share their insights on testing for biomarkers.